List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
Anthos Therapeutics Inc
Aronora Inc
Bayer AG
Bio Products Laboratory Ltd
Bristol-Myers Squibb Co
Cambryn Biologics LLC
eXithera Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Mochida Pharmaceutical Co Ltd
Ono Pharmaceutical Co Ltd
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles

7300 Series - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abelacimab [INN] - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1831865 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-2433334 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-262084 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-654457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-962212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-7041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXILRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milvexian - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7269 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7684 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osocimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-2285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones
Featured News & Press Releases
Oct 28, 2019: Ionis Pharmaceuticals presents on its drug candidate IONIS-FXI-LRx at DIA/FDA Oligonucleotide Conference
Oct 09, 2019: Ionis’ Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
Nov 13, 2017: eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017
Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Jul 04, 2016: MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI
Apr 19, 2013: CML HealthCare’s Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma
Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Anthos Therapeutics Inc, H1 2020
Pipeline by Aronora Inc, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Bio Products Laboratory Ltd, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Cambryn Biologics LLC, H1 2020
Pipeline by eXithera Pharmaceuticals Inc, H1 2020
Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Mochida Pharmaceutical Co Ltd, H1 2020
Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Dormant Projects, H1 2020

List of Figures
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• Anthos Therapeutics Inc
• Aronora Inc
• Bayer AG
• Bio Products Laboratory Ltd
• Bristol-Myers Squibb Co
• Cambryn Biologics LLC
• eXithera Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc
• Jiangsu Hengrui Medicine Co Ltd
• Mochida Pharmaceutical Co Ltd
• Ono Pharmaceutical Co Ltd